Skip to main content


Log in

Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript



Vitreous concentration of vascular endothelial growth factor (VEGF) rises significantly during proliferative diabetic retinopathy (PDR). Bevacizumab (Avastin) is a humanized monoclonal antibody to VEGF. Intravitreal administration of bevacizumab (IVB) has recently been shown to be effective in some ocular neovascularizations, including PDR. In this study we evaluate the efficacy of IVB in eyes with active, progressive PDR.


In an interventional prospective case series, eyes with active, progressive PDR underwent one to three IVB injections (1.25 mg) at intervals of either 6 or 12 weeks. Complete ophthalmic examinations and color fundus photography were performed at baseline and 1, 6, 12, and 20 weeks after the first injection. Fluorescein angiography (FA) was performed before injection and 20 weeks after. The primary outcome measures were clearing of vitreous hemorrhage (VH) and regression of active fibrovascular tissue (FVT). The secondary outcomes were any change in best-corrected visual acuity (BCVA) and any incidence of adverse events.


Thirty eight eyes of 38 patients with a mean age of 54.7 ± 10.1 years were included in the study. VH resolved significantly after 1 week (P = 0.014), 12 weeks (P = 0.0001), and 20 weeks (P = 0.002). The vascular component of FVT regressed, though the FVT area did not change. Mean BCVA improved significantly compared to baseline at all follow-up examinations. Two cases showing moderate fibrous proliferation developed traction retinal detachment (TRD).


IVB has significant therapeutic effect on eyes with active, progressive PDR: the treatment causes a significant amount of VH resolution and neovessel regression. At the same time, this procedure may increase the risk of TRD in eyes with fibrous proliferation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others


  1. Vander JF, Duker JS, Benson WE, Brown GC, McNamara JA, Rosenstein RB (1991) Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretianl photocoagulation. Ophthalmology 98:1575–1579

    PubMed  CAS  Google Scholar 

  2. The Diabetic Retinopathy Vitrectomy Study Research Group (1985) Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol 103:1643–1644

    Google Scholar 

  3. The Diabetic Retinopathy Vitrectomy Study Research Group (1988) Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision, results of a randomized trial. Diabetic Retinopathy Vitrectomy Study Report 3. Ophthalmology 95:1307–1320

    Google Scholar 

  4. Comer GM, Ciulla TA (2004) Pharmacotherapy for diabetic retinopathy. Curr Opin Ophthalmol 15:508–518, doi:10.1097/

    Article  PubMed  Google Scholar 

  5. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S et al (2000) The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 23:504–509, doi:10.2337/diacare.23.4.504

    Article  PubMed  CAS  Google Scholar 

  6. Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE (2001) Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 33:300–306, doi:10.1055/s-2001–15282

    Article  PubMed  CAS  Google Scholar 

  7. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611, doi:10.1210/er.2003–0027

    Article  PubMed  CAS  Google Scholar 

  8. Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111–118, doi:10.1097/00006982–200502000–00001

    Article  PubMed  Google Scholar 

  9. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487, doi:10.1056/NEJM199412013312203

    Article  PubMed  CAS  Google Scholar 

  10. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP (1996) Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 114:964–970

    PubMed  CAS  Google Scholar 

  11. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J et al (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114:66–71

    PubMed  CAS  Google Scholar 

  12. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA et al (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695–1705 doi:10.1016/j.ophtha.2006.05.064

    Article  PubMed  Google Scholar 

  13. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275–278, doi:10.1097/00006982–200603000–00004

    Article  PubMed  Google Scholar 

  14. Early Treatment Diabetic Retinopathy Study Research Group (1991) Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 98:823–833

    Google Scholar 

  15. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU (2006) Intravitreal Bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26(9):1006–1013, doi:10.1097/01.iae.0000246884.76018.63

    Article  PubMed  Google Scholar 

  16. Avery RL (2006) Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26:352–354, doi:10.1097/00006982–200603000–00016

    Article  PubMed  Google Scholar 

  17. Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L et al (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213–216, doi:10.1136/bjo.2007.127142

    Article  PubMed  CAS  Google Scholar 

  18. Davidorf FH, Mouser JG, Derick RJ (2006) Rapid improvement of rubeosis Iridis from a single bevacizumab injection. Retina 26:354–356, doi:10.1097/00006982–200603000–00017

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Siamak Moradian.

Additional information

The authors have no proprietary interest in this study.

The authors have full control of all primary data, and they agree to allow Graefes Archive for Clinical and Experimental Ophthalmology to review their data upon request.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moradian, S., Ahmadieh, H., Malihi, M. et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 246, 1699–1705 (2008).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: